@inproceedings{inproceedings, title  = {{1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2014}},

 month = {{2}},

 author = {{Nilsson S and Vogelzang NJ and Sartor AO and Bottomley D and Coleman RE and Skjorestad I and Wahba M and Parker C}},

 doi = {{10.1200/jco.2014.32.4_suppl.9}},

 volume = {{32}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{4_suppl}},

 pages = {{9-9}},

 note = {{Accessed on 2025/10/10}}}